Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of MGTA-456 in Patients With Inherited Metabolic Disorders (IMD) Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

Next Previous
X
Search
Trial Profile

A Phase 2, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of MGTA-456 in Patients With Inherited Metabolic Disorders (IMD) Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Spanlecortemlocel (Primary) ; Antithymocyte globulin; Busulfan; Ciclosporin; Cyclophosphamide; Fludarabine; Methylprednisolone
  • Indications Adrenoleucodystrophy; Globoid cell leukodystrophy; Metachromatic leukodystrophy; Mucopolysaccharidosis I; Transplant rejection
  • Focus Therapeutic Use
  • Sponsors Magenta Therapeutics

    • Most Recent Events

    • 22 Jun 2020 Planned end date (follow up) changed from 1 Apr 2022 to 1 Jan 2021.
    • 11 Jun 2020 According to an Magenta Therapeutics media release, the company has made a strategic decision to discontinue enrollment in this trial.This decision was the result of several factors, enrollment challenges common to rare disease populations, particularly during the COVID-19 pandemic, a growing understanding in the field of the current challenges of allogeneic stem cell transplant in patients with non-malignant diseases, such as IMDs and feedback from the FDA on endpoints and trial design.
    • 11 Jun 2020 Status changed from recruiting to discontinued, according to an Magenta Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top